Finn Ebbesen

Prof. Finn Ebbesen

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2011 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
FEFinn Ebbesen
Finn Ebbesen
JBJesper V Bjerre
Jesper V Bjerre
PVPernille K Vandborg
Pernille K Vandborg

1 July 2010 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
MDMl Donneborg
Ml Donneborg
KKKb Knudsen
Kb Knudsen
FEFinn Ebbesen
Finn Ebbesen

29 October 2014 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
PVPernille Kure Vandborg
Pernille Kure Vandborg
BHBo Mølholm Hansen
Bo Mølholm Hansen
GGGorm Greisen
Gorm Greisen
RMRené Mathiasen
René Mathiasen
FKFrederikke Kasper
Frederikke Kasper
FEFinn Ebbesen
Finn Ebbesen
Aim: To investigate whether infants with neonatal hyperbilirubinaemia but without intermediate or advanced bilirubin encephalopathy develop long‐term sequelae, with impairment of motor development, executive function, or hearing.Method: This nested double‐cohort study included 167 exposed children (107 males, 60 females) born in Denmark 2000 to 2005 at gestational age ≥35 weeks with a total serum bilirubin ≥450 μmol/L (26.3mg/dL) and 163 age‐, sex‐, and gestational age‐matched unexposed children (103 males, 60 females). The children were examined at a mean age of 7.7 years (SD 1.7y) using the Movement Assessment Battery for Children–Second Edition (MABC‐2), pure tone audiometry, and the Behavioural Regulation Inventory of Executive Function (BRIEF) questionnaire.Results: The follow‐up rate was 70% of the eligible infants in the exposed group and 45% in the unexposed group. Mean difference was −0.2 (95% confidence interval [CI] −1.1 to 0.8) in adjusted standard score for MABC‐2 and 0.3 (95% CI −2.9 to 3.5) in adjusted BRIEF executive composite standard score. No children had significant hearing impairment or a diagnosis of cerebral palsy, attention‐deficit–hyperactive disorder, or autism spectrum disorder recorded in national registries.Interpretation: No evidence was found of an increased risk of deficits in motor development, executive function, or hearing in children with extreme hyperbilirubinaemia who did not have intermediate or advanced bilirubin encephalopathy.

20 December 2016 in Acta Paediatrica
Verified
Journal Article
Open access
PDF file
HVHenrik Verder
Henrik Verder
CHChristian Heiring
Christian Heiring
HCHoward Clark
Howard Clark
DSDavid Sweet
David Sweet
TJTorben E. Jessen
Torben E. Jessen
LSLars Sørensen
Lars Sørensen
Respiratory distress syndrome (RDS) is a major cause of mortality and morbidity in premature infants. By the time symptoms appear it may already be too late to prevent a severe course, with bronchopulmonary dysplasia or mortality. We aimed to develop a rapid test of lung maturity for targeting surfactant supplementation. Concentrations of the most surface-active lung phospholipid dipalmitoylphosphatidylcholine and sphingomyelin in gastric aspirates from premature infants were measured by mass spectrometry and expressed as the lecithin/sphingomyelin ratio (L/S). The same aspirates were analysed with mid-infrared spectroscopy. Subsequently, L/S was measured in gastric aspirates and oropharyngeal secretions from another group of premature infants using spectroscopy and the results were compared with RDS development. The 10-minute analysis required 10 μL of aspirate. An L/S algorithm was developed based on 89 aspirates. Subsequently gastric aspirates were sampled in 136 infants of 24-31 weeks of gestation and 61 (45%) developed RDS. The cut-off value of L/S was 2.2, sensitivity was 92% and specificity was 73%. In 59 cases the oropharyngeal secretions had less valid L/S than gastric aspirate results. Our rapid test for lung maturity, based on spectroscopy of gastric aspirate, predicted RDS with high sensitivity.

9 July 2013 in Neonatology
Verified
Journal Article
Closed access
PDF file
HVHenrik Verder
Henrik Verder
FEFinn Ebbesen
Finn Ebbesen
JFJesper Fenger-Grøn
Jesper Fenger-Grøn
THTine Brink Henriksen
Tine Brink Henriksen
BABengt Andreasson
Bengt Andreasson
HSHristo Stanchev
Hristo Stanchev
Background: We have developed a rapid method, based on lamellar body counts (LBC) on gastric aspirate, for identifying newborns who will develop respiratory distress syndrome with a need for surfactant supplementation. Objective: We set out to test whether it was possible to improve the outcome when used in a clinical trial. Methods: We randomly assigned 380 infants born at 24-29 weeks' gestation and supported with nasal continuous positive airway pressure (nCPAP) to receive surfactant guided either by LBC (intervention group) or increasing need for oxygen (control group). The primary outcome was mechanical ventilation or death within 5 days. Secondary outcomes included need for oxygen expressed by arterial to alveolar oxygen tension ratio (a/APO2) at the age of 6 h and need for oxygen at day 28. Results: The primary outcomes were equal (25%) in the two groups. The intervention group had higher a/APO2 than the control group at 6 h, median 0.64 versus 0.52 (p < 0.01), and the subgroup with gestational age 26-29 weeks needed fewer days of oxygen supplementation than the controls, median 2 vs. 9 days (p = 0.01), and fewer infants needed oxygen at day 28 (p = 0.04). Furthermore, there was a tendency in the intervention group towards a shorter duration of nCPAP. Too little or viscose aspirate in 23% of the cases was a limitation of the method. Conclusion: Using LBC test as indicator of lung maturity and early surfactant therapy in very preterm newborns, it is possible to reduce the need for oxygen supplementation.

Verified
Journal Article
Open access
PDF file
FEFinn Ebbesen
Finn Ebbesen
HVHendrik Jan Vreman
Hendrik Jan Vreman
THThor Willy Ruud Hansen
Thor Willy Ruud Hansen
We have previously shown that the phototherapy of hyperbilirubinemic neonates using blue-green LED light with a peak wavelength of ~478 nm is 31% more efficient for removing unconjugated bilirubin from circulation than blue LED light with a peak wavelength of ~452 nm. Based on these results, we recommended that the phototherapy of hyperbilirubinemic newborns be practiced with light of ~480 nm. Aim: Identify and discuss the most prominent potential changes that have been observed in the health effects of phototherapy using either blue fluorescent- or blue LED light and speculate on the expected effects of changing to blue-green LED light phototherapy. Search the phototherapy literature using the terms neonate, hyperbilirubinemia, and phototherapy in the PubMed and Embase databases. Transitioning from blue fluorescent light to blue-green LED light will expose neonates to less light in the 400–450 nm spectral range, potentially leading to less photo-oxidation and geno-/cytotoxicity, reduced risk of cancer, and decreased mortality in extremely low-birthweight neonates. The riboflavin level may decline, and the increased production and retention of bronze pigments may occur in predisposed neonates due to enhanced lumirubin formation. The production of pre-inflammatory cytokines may rise. Hemodynamic responses and transepidermal water loss are less likely to occur. The risk of hyperthermia may decrease with the use of blue-green LED light and the risk of hypothermia may increase. Parent–neonate attachment and breastfeeding will be positively affected because of the shortened duration of phototherapy. The latter may also lead to a significant reduction in the cost of phototherapy procedures as well as the hospitalization process.